In this interview, Barry Jones and Michael Brown (Q² Solutions) discuss the current science regarding assays, the technical challenges encountered in developing assays, and how they develop assays for novel drugs.
Tuesday 29 September 2020 07:00 [PDT] 10:00 [EDT] 15:00 [BST]. Bioanalysis Zone is delighted to offer its members unique access to this panel discussion focusing on drug development and discovery post COVID-19, new developments in instrumentation and the practical implications of COVID-19 on the bioanalytical laboratory.
Webinar available on demand. Register for our exclusive Coffee Chat focusing on the quantification of biologics by LC–MS. This informal discussion centers around the use of bioanalytical strategies to support the development of bringing new biologics to market.
To celebrate International Women’s Day 2020, Bioanalysis Zone brought together a panel of experts to discuss issues surrounding gender parity in bioanalysis. This round-up summarizes our key take home messages from the expert panel.
Available on demand. Bioanalysis Zone is delighted to be bringing together a panel of experts to discuss gender parity in bioanalysis as part of a Future Science Group-wide feature to celebrate International Women’s Day 2020.
Available on demand. Live date. Bioanalysis Zone is delighted to offer its members unique access to this panel discussion focusing on new technologies. The panelists discuss how the bioanalytical field could learn from other industries and why we should be introducing new technologies.
Available on demand. Register for our exclusive Coffee Chat focusing on developments in cell and gene therapies. This informal discussion centers around gene therapy medicinal products and their potential to change the way we fight disease.
Register for our exclusive panel discussion focusing on the new ICH M10 guideline on bioanalytical method validation.
Register for our exclusive Coffee Chat focusing on patient-centric sampling. This informal discussion centers on this new type of workflow that benefits the patient, enabling the collection of previously difficult data.
We present a rare opportunity to see experts from across the pharmaceutical and CRO industries sharing perspectives on FDA guidance, transitioning skills and future hopes for the bio lab.